Volume 17, Number 3—March 2011
Research
Targeted Drug-Resistance Testing Strategy for Multidrug-Resistant Tuberculosis Detection, Lima, Peru, 2005–2008
Gustavo E. Velásquez, Martin Yagui, J. Peter Cegielski, Luis Asencios, Jaime Bayona, Cesar Bonilla, Hector O. Jave, Gloria Yale, Carmen Suárez, Sidney Atwood, Carmen C. Contreras, and Sonya S. Shin
Table 3
Prevalence estimates of TB drug resistance from national and regional surveillance data, and proportion of drug resistance in study cohort, Lima, Peru, 2005–2008*
| Cohort | Total no. patients | No. (%) susceptible to INH and RIF | No. (%) monoresistant to INH or RIF | No. (%) MDR TB |
|---|---|---|---|---|
| Peruvian NTP drug-resistance surveillance, national data (21) | ||||
| All TB patients | 2,167 | 1,829 (84.4) | 158 (7.3) | 180 (8.3) |
| New TB patients | 1,816 | 1,597 (87.9) | 124 (6.8) | 95 (5.2) |
| Previously treated patients |
351 |
232 (66.1) |
34 (9.7) |
85 (24.2) |
| Peruvian NTP drug-resistance surveillance, regional data corresponding to study area† | ||||
| All TB patients | 580 | 467 (80.5) | 41 (7.1) | 72 (12.4) |
| New TB patients | 476 | 396 (83.2) | 33 (6.9) | 47 (9.9) |
| Previously treated patients |
104 |
71 (68.3) |
8 (7.7) |
25 (24.0) |
| Study cohort | ||||
| All TB patients | 1,241 | 661 (53.3) | 161 (13.0) | 419 (33.8) |
| New TB patients | 612 | 333 (54.4) | 84 (13.7) | 195 (31.9) |
| Previously treated patients |
629 |
328 (52.2) |
77 (12.2) |
224 (35.6) |
| Study cohort, smear-positive samples only | ||||
| All TB patients | 1,114 | 581 (52.2) | 143 (12.8) | 390 (35.0) |
| New TB patients | 531 | 278 (52.4) | 73 (13.8) | 180 (33.9) |
| Previously treated patients | 583 | 303 (52.0) | 70 (12.0) | 210 (36.0) |
*TB, tuberculosis; INH, isoniazid; RIF, rifampin; MDR, multidrug resistant; NTP, National Tuberculosis Control Program.
†Ministerio de Salud, Peru, unpub. data.
Page created: July 25, 2011
Page updated: July 25, 2011
Page reviewed: July 25, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.